CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD

S V Culpitt, D F Rogers, P S Fenwick, P Shah, C De Matos, R E K Russell, P J Barnes, L E Donnelly

Thorax 2003;58:942-946

See end of article for authors' affiliations

Correspondence to:
Dr L E Donnelly,
Department of Thoracic
Medicine, National Heart
& Lung Institute, Imperial
College London,
Dovehouse Street, London
SW3 6LY, UK; l.donnelly@
imperial.ac.uk

Background: The pathophysiology of chronic obstructive pulmonary disease (COPD) features pulmonary inflammation with a predominant alveolar macrophage involvement. Bronchoalveolar macrophages from patients with COPD release increased amounts of inflammatory cytokines in vitro, an effect that is not inhibited by the glucocorticosteroid dexamethasone. Resveratrol (3,5,4'-trihydroxystilbene) is a component of red wine extract that has anti-inflammatory and antioxidant properties. A study was undertaken to determine whether or not resveratrol would inhibit cytokine release in vitro by alveolar macrophages from patients with COPD.

Methods: Alveolar macrophages were isolated from bronchoalveolar lavage (BAL) fluid from cigarette smokers and from patients with COPD ($n = 15$ per group). The macrophages were stimulated with either interleukin (IL)-1 β or cigarette smoke media (CSM) to release IL-8 and granulocyte macrophage-colony stimulating factor (GM-CSF). The effect of resveratrol was examined on both basal and stimulated cytokine release.

Results: Resveratrol inhibited basal release of IL-8 in smokers and patients with COPD by 94% and 88% respectively, and inhibited GM-CSF release by 79% and 76% respectively. Resveratrol also inhibited stimulated cytokine release. Resveratrol reduced IL-1 β stimulated IL-8 and GM-CSF release in both smokers and COPD patients to below basal levels. In addition, resveratrol inhibited CSM stimulated IL-8 release by 61% and 51% respectively in smokers and COPD patients, and inhibited GM-CSF release by 49% for both subject groups.

Conclusions: Resveratrol inhibits inflammatory cytokine release from alveolar macrophages in COPD. Resveratrol or similar compounds may be effective pharmacotherapy for macrophage pathophysiology in COPD.

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lung that is characterised by progressive and irreversible airflow limitation.¹ The major risk factor for development of COPD is cigarette smoking, and the only intervention that slows disease progression is smoking cessation.²⁻³ The inflammatory cell profile in COPD includes macrophages, neutrophils, and T lymphocytes.⁴

Macrophages are implicated as coordinators of the pulmonary inflammation and parenchymal damage of COPD.¹ For example, numbers of alveolar macrophages are increased in the lungs of patients with COPD,⁵⁻⁶ and macrophages from these patients release increased levels of cytokines⁷ and proteases⁸⁻⁹ compared with macrophages from control subjects. The macrophages contribute to airway inflammation in smokers and COPD patients by secreting neutrophil and macrophage chemotactic factors such as interleukin 8 (IL-8),¹⁰⁻¹¹ cell survival factors such as granulocyte macrophage-colony stimulating factor (GM-CSF),⁷ and by the generation of reactive oxygen species.¹²

Current treatment for COPD is, for the most part, palliative and does not appear to inhibit disease progression.³⁻¹³ Although corticosteroids are an effective treatment for asthma,¹⁴ their efficacy in stable COPD is controversial.¹⁵⁻¹⁶ Consequently, alternative therapeutic approaches are being sought.¹⁷ Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic molecule found in the skins of red fruits such as grapes, and is one of the compounds in red wine extract that exhibits a range of biological activities.¹⁸ It has antioxidant, antineoplastic, and anti-inflammatory properties.¹⁹⁻²¹ For

these reasons, resveratrol is thought to contribute to the health benefits ascribed to the consumption of red wine.²²

The aim of the present study was to examine the effect of resveratrol on cytokine release by alveolar macrophages from patients with COPD. We therefore determined whether or not resveratrol would inhibit basal and IL-1 β or cigarette smoke medium (CSM) stimulated release of IL-8 and GM-CSF by macrophages from cigarette smokers and patients with COPD. We used IL-1 β as an inflammatory stimulant because it is increased in bronchoalveolar lavage (BAL) fluid of cigarette smokers.²³ CSM was used because of the association between cigarette smoking and development of COPD,² and because CSM induces release of cytokines⁷ and proteases⁸ by BAL fluid alveolar macrophages.

METHODS

Patients

The 15 patients with COPD and 15 cigarette smoking control subjects reported here are the same as those described elsewhere.⁷ The COPD patients fulfilled the criteria of the British Thoracic Society²⁴ with forced expiratory volume in 1 second (FEV₁) % predicted less than 70% and a ratio of FEV₁ to forced vital capacity (FVC) of less than 0.7 (table 1). The smokers were without airway obstruction (FEV₁ >80% predicted, table 1). All subjects were current smokers and had a smoking history of >20 pack years. The subjects with COPD maintained their medication (β_2 agonists, $n = 14$; anticholinergics, $n = 15$; inhaled corticosteroids, $n = 6$). Smokers were unmedicated. The study was approved by the Riverside ethics committee and the ethics committee of the

Table 1 Clinical characteristics of healthy smokers and patients with COPD

Parameter	Smokers	COPD
Age (years)	54 (3)	68 (2)**
Sex (M:F)	11:4	12:3
Pack years	29 (3)	37 (4)*
FEV ₁ (l)	2.9 (0.2)	1.8 (0.1)***
FEV ₁ (% predicted)	93 (2)	54 (5)***
FEV ₁ :FVC ratio	0.84 (0.02)	0.53 (0.03)***

Data are mean (SE).

FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity.

*p<0.05, **p<0.01, ***p<0.001 compared with equivalent value for smokers.

Royal Brompton and Harefield NHS Trust. Subjects gave informed written consent.

Bronchoalveolar lavage

All subjects were asked to refrain from smoking from the night before BAL fluid sampling (approximately 12 hours). BAL fluid was collected as described previously⁷ by sequential instillation and aspiration of 60 ml warmed 0.9% (w/v) normal saline, up to a maximum of 240 ml. Subjects were monitored with digital oximetry.

Isolation and culture of alveolar macrophages

Alveolar macrophages were isolated from the BAL fluid as described previously.⁷ The macrophages were resuspended in RPMI-1640 medium containing 10% (v/v) fetal calf serum, 2 mM L-glutamine, 100 iu/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin. Cells were seeded in 24-well Falcon cell culture plates (Becton Dickinson, Cowley, Oxfordshire, UK) at a density of 250 000 cells/well and incubated (37°C, 5% CO₂, humidified air) for 2 hours to allow macrophage adherence. The medium was replaced and non-adherent cells removed by aspiration. The macrophages were cultured for 24 hours, after which the medium was replaced and cells cultured for a further 24 hours under experimental conditions. Resveratrol and the stimulants were co-administered at time zero. Ten µg/ml IL-1β was used because we have found previously that this concentration gives a consistent stimulation of both IL-8 and GM-CSF release.⁷ Cell viability was determined following experimental treatments using trypan blue dye exclusion.

Production of CSM and measurement of endotoxin

CSM was produced as described previously.⁷ Smoke from two cigarettes (12 mg tar, 0.9 mg nicotine) was bubbled through 20 ml culture medium and, to ensure standardisation between experiments and batches of CSM, the absorbance was adjusted by dilution to 0.15 at 320 nm using the method of Wirtz and Schmidt.²⁵ This concentration (nominally 1) is not cytotoxic (see Results below) and was serially diluted with untreated media (0.001- to 1-fold) and applied to the macrophages. The concentration of endotoxin in a 1-fold dilution of CSM was measured using a QCL-1000 endotoxin kit (BioWhittaker, Walkersville, MD, USA) according to the manufacturer's instructions. The limit of detection of the assay was 0.1 endotoxin unit (EU)/ml.

Cytokine measurements

IL-8 and GM-CSF were measured in macrophage culture supernatants using paired antibody quantitative ELISAs (R&D Systems, Abingdon, Oxfordshire, UK).⁷ The lower limit of detection was 15.6 pg/ml for both assays, with a coefficient of variation of 24% for the IL-8 assay and of 17% for the GM-CSF assay. In order to determine whether or not resveratrol affected the cytokine ELISAs, standard curves were constructed in the absence and presence of resveratrol (100 µM).

Statistical analysis

Concentrations of macrophage cytokines between treatment and controls and between COPD patients and smokers were compared using repeated measures analysis of variance (ANOVA). Where differences were found, the minimum value following treatment was taken as a summary measurement. The concentration of resveratrol causing 50% inhibition of stimulated cytokine release (IC₅₀ value) was calculated using GraphPad Prism software (GraphPad Software Inc, San Diego, CA, USA). Data are presented as means with 95% confidence intervals (CI) unless stated otherwise.

RESULTS

We have previously reported that there was no difference in the number of inflammatory cells recovered or macrophage number in BAL fluid between the two groups.⁷ None of the experimental interventions affected the viability of the macrophages. Resveratrol did not affect the ELISA cytokine measurements; slopes of standard curves for IL-8 were 0.00085 (SE 0.00011) in the absence of resveratrol and 0.00083 (SE 0.00010) in the presence of resveratrol, and for

Figure 1 Effect of resveratrol on basal cytokine release by alveolar macrophages from cigarette smokers (□) and patients with COPD (■). Data are presented as mean (SE) concentrations of (A) IL-8 and (B) GM-CSF for 15 subjects in each group. For some data points SE values are within the symbol. ***p<0.001 versus control.

Table 2 Inhibition by resveratrol of basal or stimulated cytokine release from alveolar macrophages

Stimulus	Cytokine	Smokers	COPD
Basal	IL-8	7.4 (0.4)	6.9 (0.4)
	GM-CSF	7.0 (0.1)	6.8 (0.1)
IL-1 β	IL-8	6.7 (0.1)	6.2 (0.4)
	GM-CSF	6.9 (0.2)	6.9 (0.3)
CSM	IL-8	6.4 (0.3)	7.4 (1.2)
	GM-CSF	7.1 (0.3)	6.7 (0.2)

COPD = chronic obstructive pulmonary disease; CSM = cigarette smoke medium; IL = interleukin; GM-CSF = granulocyte macrophage-colony stimulating factor.

Values are mean (SE) IC₅₀ values expressed as $-\log$ [resveratrol] (M) (n = 15 per group).

GM-CSF the values were 0.0011 (SE 0.0001) and 0.0012 (SE 0.0001), respectively.

Effect of resveratrol on basal cytokine release

Basal IL-8 release from macrophages was approximately five times greater in patients with COPD than in smokers (262 pg/ml (95% CI 235 to 290) ν 50 pg/ml (95% CI 45 to 57), fig 1A). Resveratrol inhibited basal IL-8 release by macrophages from both smokers (by 94% at 100 μ M) and patients with COPD (by 88%, fig 1A). In contrast to IL-8 release, basal release of GM-CSF was similar in the two groups (724 pg/ml (95% CI 686 to 763) ν 737 pg/ml (95% CI 697 to 777), fig 1B). Resveratrol inhibited GM-CSF release by macrophages from smokers and patients with COPD by 79% and 76%, respectively, at 100 μ M (fig 1B). There was no significant difference between the IC₅₀ values for inhibition by resveratrol of basal IL-8 or GM-CSF release by macrophages from smokers or patients with COPD (table 2).

Effect of resveratrol on cytokine release induced by IL-1 β

Exposure of macrophages from smokers or COPD patients to IL-1 β (10 ng/ml) increased IL-8 release by 1.8-fold (50 pg/ml (95% CI 45 to 57) ν 87 pg/ml (95% CI 83 to 91)) and 1.3-fold (262 pg/ml (95% CI 235 to 290) ν 328 pg/ml (95% CI 306 to 351)), respectively, above basal values (fig 2A). Similarly, IL-1 β increased GM-CSF release by approximately 1.8-fold above basal values in both groups (737 pg/ml (95% CI 697 to 777) ν 1327 pg/ml (95% CI 1223 to 1431) and 724 pg/ml (95% CI 686 to 763) ν 1348 pg/ml (95% CI 1148 to 1547),

respectively; fig 2B). Resveratrol inhibited IL-1 β stimulated IL-8 release and GM-CSF release by macrophages from both smokers and patients with COPD to below their respective basal levels (fig 2A and B). There was no significant difference in IC₅₀ values for inhibition by resveratrol of IL-1 β stimulated IL-8 or GM-CSF release by macrophages from smokers and patients with COPD (table 2).

Effect of resveratrol on cytokine release induced by CSM

Exposure of macrophages from smokers or patients with COPD to CSM (1 fold dilution) increased IL-8 release by ~3-fold (50 pg/ml (95% CI 45 to 57) ν 141 pg/ml (95% CI 128 to 154)) and ~2-fold (262 pg/ml (95% CI 235 to 290) ν 542 pg/ml (95% CI 518 to 265)), respectively, above basal values (fig 3A). Similarly, CSM increased GM-CSF release by ~2-fold (737 pg/ml (95% CI 697 to 777) ν 1493 pg/ml (95% CI 1398 to 1587)) and 2.7-fold (724 pg/ml (95% CI 686 to 763) ν 1977 pg/ml (95% CI 1873 to 2081)) above basal values in smokers and COPD patients, respectively (fig 3B). The concentration of endotoxin in the CSM was below the level of detection of the assay (<0.1 EU/ml).

Resveratrol inhibited CSM stimulated IL-8 release by macrophages from smokers and patients with COPD by 61% and 51%, respectively (fig 3A). Similarly, resveratrol inhibited GM-CSF release by macrophages from smokers to basal levels and by macrophages from COPD patients by 49% (fig 3B). There was no significant difference between the IC₅₀ values for inhibition by resveratrol of CSM stimulated IL-8 and GM-CSF release by macrophages from smokers and patients with COPD (table 2).

DISCUSSION

IL-1 β or CSM stimulated cytokine release by BAL fluid alveolar macrophages from cigarette smokers and COPD patients, effects which have been described previously by us⁷ and by others.²⁶ The increased basal levels of IL-8 release by macrophages from patients with COPD seen here are unlikely to be due to inhaled bronchodilator medication because β_2 adrenoceptor agonists inhibit rather than stimulate cytokine release from differentiated U937 human macrophage-like cells,²⁷ while acetylcholine stimulates cytokine release from bovine alveolar macrophages,²⁸ an effect that would be counteracted by ipratropium bromide, leading to decreased cytokine levels. CSM stimulation of cytokine release is unlikely to be due to the presence of endotoxin in the CSM because

Figure 2 Effect of resveratrol on IL-1 β stimulated cytokine release by alveolar macrophages from smokers (□) and patients with COPD (■). Data are mean (SE) concentrations of (A) IL-8 or (B) GM-CSF for 15 subjects in each group. For some data points SE values are within the symbol. ***p<0.001 versus control (IL-1 β stimulated, 10 ng/ml); ordinate is split in panel A. The dashed line is the basal value for smokers and the dotted line is the basal value for patients with COPD.

Figure 3 Effect of resveratrol on cigarette smoke medium (CSM) stimulated cytokine release by alveolar macrophages from smokers (□) and patients with COPD (■). Data are mean (SE) concentrations of (A) IL-8 and (B) GM-CSF for 15 subjects in each group. For some data points SE values are within the symbol. *** $p < 0.001$ versus control (CSM stimulated, $1 \times$ dilution); ordinate is split in panel A. The dashed line is the basal value for smokers and the dotted line is the basal value for patients with COPD.

endotoxin was not detected in the media. With reference to the validity of comparison of the effects of CSM *in vitro* to *in vivo* cigarette smoke exposure, the relationship between CSM and exposure of macrophages to cigarette smoke *in vivo* is not known. However, in rats CSM and cigarette smoke *in vivo* induce similar patterns of DNA damage.²⁹ Although not measured specifically in the present study, differences in BAL fluid cytokine and inflammatory mediator concentrations between patients with COPD and smoking controls may influence subsequent macrophage responses.

We found that resveratrol inhibited both basal and stimulated cytokine release by BAL fluid macrophages from cigarette smokers and patients with COPD. This is consistent with the inhibitory effects of resveratrol in a variety of cell preparations, including macrophages. For example, resveratrol inhibited IL-12 and TNF α release³⁰ and IL-6 release³¹ by murine peritoneal macrophages. It is noteworthy that, in the present study, the inhibition of cytokine release by resveratrol was similar for both IL-8 and GM-CSF and for both subject groups, as evidenced by the IC₅₀ values (table 2). The mechanism of the inhibition by resveratrol of cytokine release is not explored in the present study. However, inhibition of cytokine release may be due to suppression of NF- κ B and AP-1 activation,³² with a consequent reduction in inflammatory cytokine expression. Suppression of NF- κ B may involve a decrease in the phosphorylation and, hence, degradation of I- κ B α .^{33–34} For the inhibition of CSM induced cytokine release, resveratrol is an antioxidant¹⁸ and an antagonist for the receptor for aryl hydrocarbons which are found in cigarette smoke.³⁵ These properties would both be consistent with inhibition of CSM induced responses.

We have previously found that the glucocorticosteroid dexamethasone did not inhibit IL-8 release by BAL fluid macrophages from patients with COPD.⁷ This is in contrast to the marked inhibition observed in the present study by resveratrol in these same patient groups. In particular, resveratrol inhibited CSM stimulated GM-CSF release from both patient groups, whereas dexamethasone had no inhibitory effect except at a high concentration (10 μ M) in smokers. The reasons underlying these apparent differential inhibitory effects of resveratrol and dexamethasone are unclear, but may be due to the antioxidant properties of resveratrol in addition to its anti-inflammatory activity.

Current treatment for the lung inflammation in stable COPD is suboptimal, with clinical use of glucocorticosteroids

being controversial.^{15–16} Any lack of corticosteroid efficacy could be the result of reduced steroid sensitivity by pulmonary macrophages.⁷ In the present study we found that resveratrol inhibits basal and stimulated cytokine release by BAL macrophages in COPD patients. Specifically, resveratrol inhibited release of the neutrophil chemotactic factor IL-8 and the cell survival cytokine GM-CSF. This could lead to inhibition of neutrophilia and decreased levels of inflammatory cytokines in the airways of patients with COPD. Thus, resveratrol or related compounds may be more effective pharmacotherapeutic compounds than corticosteroids for the treatment of chronic stable COPD. A possible clinical disadvantage of resveratrol is its low bioavailability. Consequently, resveratrol analogues such as piceatannol are under investigation.³⁶

ACKNOWLEDGEMENTS

This study was supported by a Training Fellowship from the Medical Research Council, UK (SVC), Bayer plc, Stoke Poges, UK (CDM), and the British Lung Foundation (REKR).

Authors' affiliations

S V Culpitt, D F Rogers, P S Fenwick, P Shah, C De Matos, R E K Russell, P J Barnes, L E Donnelly, Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College London, London SW3 6LY, UK

REFERENCES

- Barnes PJ. New concepts in chronic obstructive pulmonary disease. *Annu Rev Med* 2003;**54**:113–29.
- Scanlon PD, Connett JE, Waller LA, *et al.* Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. *Am J Respir Crit Care Med* 2000;**161**:381–90.
- Culpitt SV, Rogers DF. Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2000;**1**:1007–20.
- Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. *Chest* 2000;**117**:251S–60S.
- Linden M, Rasmussen JB, Piitulainen E, *et al.* Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. *Am Rev Respir Dis* 1993;**148**:1226–32.
- Abboud RT, Ofulue AF, Sansores RH, *et al.* Relationship of alveolar macrophage plasminogen activator and elastase activities to lung function and CT evidence of emphysema. *Chest* 1998;**113**:1257–63.
- Culpitt SV, Rogers DF, Shah P, *et al.* Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;**167**:24–31.
- Russell RE, Culpitt SV, DeMatos C, *et al.* Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2002;**26**:602–9.

- 9 Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. *Am J Physiol Lung Cell Mol Physiol* 2002;**283**:L867–73.
- 10 Lohmann-Matthes ML, Steinmüller C, Franke-Ullmann G. Pulmonary macrophages. *Eur Respir J* 1994;**7**:1678–89.
- 11 Mio T, Romberger DJ, Thompson AB, et al. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. *Am J Respir Crit Care Med* 1997;**155**:1770–6.
- 12 Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. *Am J Pathol* 1982;**107**:395–418.
- 13 National Heart, Lung and Blood Institute World Health Organisation. *Global initiative for chronic obstructive lung disease*. Publication No 2701. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 2001.
- 14 National Institutes of Health. *Global initiative for asthma: pocket guide for asthma management and prevention*. Publication No 02-3659. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute, 2002.
- 15 Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:341–2.
- 16 Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:342–4.
- 17 Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. *Drugs* 2003;**63**:1973–98.
- 18 Fremont L. Biological effects of resveratrol. *Life Sci* 2000;**66**:663–73.
- 19 Martinez J, Moreno JJ. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. *Biochem Pharmacol* 2000;**59**:865–70.
- 20 Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. *Drugs Exp Clin Res* 1999;**25**:65–77.
- 21 Sgambato A, Ardito R, Faraglia B, et al. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. *Mutat Res* 2001;**496**:171–80.
- 22 Soleas GJ, Diamandis EP, Goldberg DM. The world of resveratrol. *Adv Exp Med Biol* 2001;**492**:159–82.
- 23 Ekberg-Jansson A, Andersson B, Bake B, et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. *Respir Med* 2001;**95**:363–73.
- 24 British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. *Thorax* 1997;**52**(suppl 5):S1–28.
- 25 Wirtz HR, Schmidt M. Acute influence of cigarette smoke on secretion of pulmonary surfactant in rat alveolar type II cells in culture. *Eur Respir J* 1996;**9**:24–32.
- 26 Dubar V, Gosset P, Aerts C, et al. In vitro acute effects of tobacco smoke on tumor necrosis factor alpha and interleukin-6 production by alveolar macrophages. *Exp Lung Res* 1993;**19**:345–59.
- 27 Izeboud CA, Mocking JA, Monshouwer M, et al. Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. *J Recept Signal Transduct Res* 1999;**19**:191–202.
- 28 Sato E, Koyama S, Okubo Y, et al. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. *Am J Physiol* 1998;**274**:L970–9.
- 29 Randerath E, Danna TF, Randerath K. DNA damage induced by cigarette smoke condensate in vitro as assayed by 32P-postlabeling. Comparison with cigarette smoke-associated DNA adduct profiles in vivo. *Mutat Res* 1992;**268**:139–53.
- 30 Gao X, Xu YX, Janakiraman N, et al. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. *Biochem Pharmacol* 2001;**62**:1299–308.
- 31 Zhong M, Cheng GF, Wang WJ, et al. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. *Phytomedicine* 1999;**6**:79–84.
- 32 Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. *J Immunol* 2000;**164**:6509–19.
- 33 Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. *Ann NY Acad Sci* 2002;**957**:210–29.
- 34 Surh YJ, Chun KS, Cha HH, et al. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: downregulation of COX-2 and iNOS through suppression of NF-kappa B activation. *Mutat Res* 2001;**480–481**:243–68.
- 35 Casper RF, Quesne M, Rogers IM, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. *Mol Pharmacol* 1999;**56**:784–90.
- 36 Wieder T, Prokop A, Bagci B, et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. *Leukemia* 2001;**15**:1735–42.